Full-Time

Vice President Regional Marketing

Infection Prevention & Surgical Solutions

Posted on 9/10/2026

Solventum

Solventum

10,001+ employees

Global healthcare company: wound care, dental

No salary listed

Minnesota, USA

Remote

May include up to 50% international travel.

Bachelor's

Category
Growth & Marketing (1)
Required Skills
Marketing

Get referred to Solventum

See people who can refer or advise you

Requirements
  • A bachelor's degree or higher and 10 or more years of marketing-related experience, or a high school diploma/GED and 20 or more years of marketing-related experience.
  • At least 5 years of senior marketing leadership experience in regional and multi-country roles.
  • Strong background in downstream marketing, go-to-market execution, and global sales enablement.
  • Proven ability to manage budgets, prioritize investments, and demonstrate return on investment over both long-term and fiscal-year horizons.
  • Experience operating in matrixed global and regional organizations with critical shared resources.
  • Strong cross-functional leadership, communication, and stakeholder-management skills.
Responsibilities
  • Own and execute the regional marketing plan in alignment with global downstream marketing strategies and regional business priorities.
  • Serve as the primary marketing interface to Regional Business Leaders, Sales leadership, and key cross-functional partners.
  • Ensure marketing programs drive measurable growth, return on investment, and market share expansion in priority segments.
  • Lead regional execution of global campaigns, new product introductions, and demand-generation initiatives, adapting messaging and tactics to local market needs.
  • Drive sales enablement by translating global value propositions into regionally relevant tools, content, and programs.
  • Ensure launch excellence for new product introductions through coordinated planning, training, and activation across the region.
  • Own regional marketing budgets, including allocation to cross-functional initiatives, tracking, and reprioritization in alignment with growth objectives.
  • Partner with Finance and Global Marketing to improve visibility, governance, and return-on-investment reporting on marketing investments.
  • Lead, mentor, and develop a team of regional marketers.
  • Set performance expectations, provide coaching, and foster skill growth.
  • Champion continuous improvement of downstream marketing skills, capabilities, processes, and tools.
  • Create a culture of accountability, innovation, and strategic and financial rigor.
  • Ensure corporate policies, procedures, and security standards are complied with while performing assigned duties.
Desired Qualifications
  • Strategy to Execution: Translate strategy into clear, outcome-driven plans.
  • Structured Problem Solving: Cut through complexity to focus on what matters most.
  • Enterprise Influence: Align teams and drive action across functions and levels.
  • Investment Mindset: Allocate resources with discipline to maximize return on investment.
  • Enterprise-First, Low Ego: Prioritize company success over individual recognition.
  • Execution-Oriented: Drive pace, accountability, and results.
  • Clarity in Ambiguity: Bring structure and direction in complex environments.
  • Trust Builder: Earn credibility quickly and build strong cross-functional partnerships.

Solventum provides a wide range of healthcare products across four main areas: wound care and surgical supplies, dental and orthodontic tools, health information software, and purification filters for biopharmaceuticals. These products work by combining material science and data science to help hospitals manage patient records, prevent infections during surgery, and filter fluids for medical treatments like dialysis. Unlike many competitors, the company holds a massive portfolio of over 7,300 patents inherited from its history as a 3M division, allowing it to serve over 75% of U.S. hospitals. Its goal is to use this intellectual property and a disciplined business model to find new solutions for healthcare providers and grow within the global medical technology market.

Company Size

10,001+

Company Stage

IPO

Headquarters

Maplewood, Minnesota

Founded

2023

Get referred to Solventum

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 organic sales rose 9.5%, and management lifted EPS guidance to $7.10-$7.20.
  • Dental grew 15.2% organically in Q2 2026, showing pricing and product momentum.
  • Solventum exited nearly 70% of TSAs and targets 90% by end-2026.

What critics are saying

  • ERP advance orders inflated Q2 by about $125 million, and Q3 reverses.
  • HIS now faces separation, and AI-native competitors threaten revenue-cycle workflows by 2027.
  • Thermo Fisher's $4.1 billion filtration acquisition removes Solventum's fastest-growing cash engine.

What makes Solventum unique

  • Solventum controls 3M-origin IP, with 7,300 patents across MedSurg, dental, and filtration.
  • Its $200 million Eagan Innovation Hub centralizes wound care, sterilization, and digital health R&D.
  • Management expects nearly 20 launches through Q1 2028, anchoring category depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

8%
Yahoo Finance
Aug 20th, 2026
BrightSpring Health Services posts 23.9% revenue growth as Solventum and Inspire Medical face headwinds

BrightSpring Health Services stands out as a strong long-term healthcare investment, whilst Solventum and Inspire Medical Systems face headwinds, according to recent analysis. Healthcare stocks have surged 27.5% over the past six months, outperforming the S&P 500 by 16.2 percentage points. However, increased venture capital has intensified competition across the sector. BrightSpring, which provides home health care, hospice, and pharmacy services, has achieved 23.9% annual revenue growth over the past two years. Analysts forecast 14.1% revenue growth for the next 12 months. Conversely, Solventum faces weak demand with flat revenue expected, whilst its free cash flow margin has declined 18.2 percentage points over five years. Inspire Medical Systems confronts a forecasted revenue decline of 3.5% for the upcoming year.

Yahoo Finance
Aug 11th, 2026
Solventum beats Q2 estimates with $2.21B revenue, raises EPS guidance 10% amid HIS separation

Healthcare solutions provider Solventum reported second quarter revenue of $2.21 billion, up 2.2% year on year and ahead of analyst estimates of $2.15 billion. Non-GAAP profit of $2.55 per share beat consensus estimates by 33.8%. The company announced plans to separate its Health Information Systems business to focus on its MedSurg and Dental segments. Management said the move would allow the HIS unit to pursue AI-driven innovation whilst sharpening Solventum's focus as a pure-play MedTech company. Second quarter results were temporarily boosted by approximately $125 million in advanced orders placed ahead of a major ERP system transition, which management expects to reverse next quarter. The company raised its full-year adjusted EPS guidance to $7.15 at the midpoint, a 10% increase. Solventum is nearing completion of its separation from 3M.

Yahoo Finance
Aug 9th, 2026
Solventum raises 2026 outlook with 9.5% Q2 growth boosted by $125M advanced orders and $100M tariff refund

Solventum exceeded expectations in Q2, posting $2.2 billion in sales with 9.5% organic growth. However, this included roughly $125 million in advanced ERP-related orders and a $100 million tariff refund. Excluding these benefits, organic growth was approximately 4% and adjusted EPS was estimated at $1.73. The company raised its 2026 outlook, now expecting 2.5%–3% organic sales growth, a 22.2%–22.7% operating margin, adjusted EPS of $7.10–$7.20, and free cash flow of $200 million–$300 million. Third-quarter growth is expected to decline temporarily as the advanced orders reverse. Solventum also announced plans to separate its Health Information Systems business through a potential spin-off or sale, aiming to focus on its MedSurg and Dental segments.

PR Newswire
Aug 5th, 2026
Solventum Q2 sales up 9.5%, raises 2026 guidance and plans to separate Health Information Systems unit

Solventum reported second quarter 2026 sales of $2.2 billion, up 2.2% on a reported basis and 9.5% organically. The MedTech company posted GAAP diluted earnings per share of $0.53 and adjusted diluted EPS of $2.55, marking a 50.9% increase. Operating cash flow reached $227 million, whilst free cash flow totalled $144 million. The strong performance was driven by volume and product mix across all segments, including advance orders ahead of ERP cutovers. Solventum announced plans to separate its Health Information Systems business segment as part of its transformation strategy. The company raised its full-year 2026 guidance, increasing organic sales growth to 2.5% to 3.0%, adjusted EPS to $7.10 to $7.20, and free cash flow to $200 million to $300 million.

Yahoo Finance
Aug 2nd, 2026
Solventum appoints Neil Zieselman as chief accounting officer

Solventum has appointed Neil Zieselman as Senior Vice President, Controller, and Chief Accounting Officer. He will succeed Mary Wilcox, who is retiring. Zieselman brings experience from Surgery Partners, Stryker Corporation, Covanta Holding Corporation, Cendant Corporation, and Avaya. He is a licensed CPA. The company's stock trades at $85.44. It has delivered a 9.5% return over the past week and 19.1% over the past year. For investors, Zieselman's background in healthcare and corporate finance may influence Solventum's financial controls, reporting quality, and regulatory engagement. His approach could shape disclosure practices and capital allocation commentary in future earnings calls. Interest payments are not well covered by earnings, making any changes under the new Chief Accounting Officer particularly important for risk assessment.